Drs. Eli Ben-Chetrit and Avraham Ben-Chetrit contributed equally to this work.
Familial Mediterranean Fever
Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?
Article first published online: 28 JAN 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 2, pages 143–148, February 2010
How to Cite
Ben-Chetrit, E., Ben-Chetrit, A., Berkun, Y. and Ben-Chetrit, E. (2010), Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?. Arthritis Care Res, 62: 143–148. doi: 10.1002/acr.20061
- Issue published online: 28 JAN 2010
- Article first published online: 28 JAN 2010
- Manuscript Accepted: 1 OCT 2009
- Manuscript Received: 1 JUL 2009
- Canadian Friends of the Hebrew University
To evaluate the outcome of pregnancies in women with familial Mediterranean fever (FMF) who are taking colchicine, and to reconsider the justification for amniocentesis in these women.
The outcome of 179 pregnancies in a group of women with FMF taking colchicine was compared with the outcome of 197 pregnancies in women with FMF who did not take colchicine during pregnancy and with 312 pregnancies in another cohort of healthy pregnant women of similar age and ethnicity.
There was no difference in the 3 groups regarding early abortions, late abortions, or congenital malformations. There was a mild trend towards a better outcome for the colchicine-treated group but these results did not reach statistical significance.
Treatment with colchicine during pregnancy in patients with FMF is beneficial in controlling the disease while not affecting the outcome of the pregnancy; therefore there is no justification for recommending amniocentesis in women taking colchicine solely because of this treatment.